Apyx Medical Corp: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 7, 2019 and accepted by EDGAR at Aug 7, 2019, 17:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $6.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $12.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $2.1m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $4.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $4.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $8.2m | us-gaap:GrossProfit |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $888.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $1.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-04-01 to 2019-06-30 | $3.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2019-01-01 to 2019-06-30 | $6.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$4.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$9.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $0 | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $0 | us-gaap:InterestExpense |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $76.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | −$48.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$4.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$9.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$270.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | −$270.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$10.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $922.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $67.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $82.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $88.9m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $7.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $8.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $80.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000719135-19-000039. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.